Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer : potential targets for chemoprevention and systemic therapy
Richardson, C. M., Sharma, R. A., Cox, G., & O'Byrne, Kenneth J. (2003) Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer : potential targets for chemoprevention and systemic therapy. Lung Cancer, 39(1), pp. 1-13.
The epidermal growth factor receptor (EGFR) is part of a family of plasma membrane receptor tyrosine kinases that control many important cellular functions, from growth and proliferation to cell death. Cyclooxygenase (COX)-2 is an enzyme which catalyses the conversion of arachidonic acid to prostagladins and thromboxane. It is induced by various inflammatory stimuli, including the pro-inflammatory cytokines, Interleukin (IL)-1β, Tumour Necrosis Factor (TNF)-α and IL-2. Both EGFR and COX-2 are over-expressed in non-small cell lung cancer (NSCLC) and have been implicated in the early stages of tumourigenesis. This paper considers their roles in the development and progression of lung cancer, their potential interactions, and reviews the recent progress in cancer therapies that are directed toward these targets. An increasing body of evidence suggests that selective inhibitors of both EGFR and COX-2 are potential therapeutic agents for the treatment of NSCLC, in the adjuvant, metastatic and chemopreventative settings. © 2002 Elsevier Science Ireland Ltd. All rights reserved.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Angiogenesis, Cyclooxygenase, Epidermal growth factor receptor, Matrix metalloproteinases, Non-small cell lung cancer, Tyrosine kinase inhibitors, 6 (4 hydroxyphenyl) 4 (alpha methylbenzylamino) 7h pyrrolo[2, 3 d]pyrimidine, arachidonic acid, canertinib, celecoxib, cyclooxygenase 2, cyclooxygenase 2 inhibitor, cytokine, diclofenac, erlotinib, gefitinib, ibuprofen, indometacin, interleukin 1beta, interleukin 2, matrix metalloproteinase, meloxicam, pelitinib, piroxicam, prostaglandin, protein inhibitor, protein tyrosine kinase, rofecoxib, thromboxane, tumor necrosis factor alpha, cancer adjuvant therapy, cancer growth, cancer therapy, carcinogenesis, catalyst, cell death, cell growth, cell invasion, cell proliferation, cell transformation, cellular immunity, chemoprophylaxis, cigarette smoking, clinical trial, diarrhea, down regulation, fatigue, human, immune response, immunosuppressive treatment, inflammation, lung non small cell cancer, metastasis, nausea, nonhuman, priority journal, protein expression, protein function, protein interaction, rash, review, side effect, signal transduction, stomatitis, systemic therapy, target organ, vomiting, Carcinoma, Non-Small-Cell Lung, Clinical Trials, Humans, Isoenzymes, Lung Neoplasms, Membrane Proteins, Prostaglandin-Endoperoxide Synthases, Receptor, Epidermal Growth Factor|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2003 Elsevier|
|Deposited On:||13 Dec 2013 00:40|
|Last Modified:||13 Dec 2013 00:40|
Repository Staff Only: item control page